Quick Answer
Emmaus Life Sciences, Inc. reported Stockholders Equity of -$63.61 million for fiscal year 2025.
Emmaus Life Sciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$63.61M | -12.6% |
| 2024 | -$56.48M | -18.3% |
| 2023 | -$47.76M | -40.1% |
| 2022 | -$34.09M | -58.9% |
| 2021 | -$21.45M | -315.9% |
| 2020 | -$5.16M | +53.3% |
| 2019 | -$11.05M | +9.8% |
| 2019 | -$12.25M | +43.6% |
| 2018 | -$21.71M | -639.9% |
| 2018 | $4.02M | -78.0% |
| 2017 | $18.29M | +302.2% |
| 2017 | $4.55M | +527.2% |
| 2016 | -$1.06M | +78.0% |
| 2015 | -$4.84M | -174.6% |
| 2014 | -$1.76M | +18.4% |
| 2013 | -$2.16M | +83.5% |
| 2012 | -$13.07M | -14.5% |
| 2011 | -$11.42M | -171.7% |
| 2010 | -$4.20M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$59.49M | -10.6% | -6.8% |
| June 30, 2025 | -$55.70M | +2.3% | +4.9% |
| March 31, 2025 | -$58.60M | -9.2% | -3.8% |
| December 31, 2024 | -$56.48M | -18.3% | -5.0% |
| September 30, 2024 | -$53.78M | -48.0% | +5.7% |
| June 30, 2024 | -$57.01M | -62.7% | -6.3% |
| March 31, 2024 | -$53.64M | -43.6% | -12.3% |
| December 31, 2023 | -$47.76M | -40.1% | -31.5% |
- Emmaus Life Sciences, Inc. showed a decrease of -12.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2010–2025 period, Emmaus Life Sciences, Inc.’s stockholders equity has declined by 1412.9% (from -$4.20 million to -$63.61 million).
- The most recent figure is from Emmaus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: